BioSpace News Archive

Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited fourth quarter 2020 net sales of approximately $118 million, a decrease of 3% on a reported basis and 4% on a constant currency basis.

FineHeart, SA, a preclinical-stage medical device company developing an Implantable Cardiac Output Management System (ICOMS) to address the unmet need of patients suffering from severe heart failure, today announced the successful completion of a seven-day study of its Transcutaneous Energy Transfer (TET) System for recharging the ICOMS implantable battery.

Anticipates $2.3 Million Revenue in Fourth Quarter, $8.5 Million in Full-Year; Quarterly Revenue Grew 9% Sequentially Over Third Quarter; Full Year Revenue Declined 17%

The ewing’s sarcoma treatment market is expected to witness robust growth in the near future. the market is likely to benefit from the dramatic improvements in cancer survival rates over the years.

Physical disability can be very traumatic for a human being. Irrespective of the cause of the disability, it has a deep psychological effect on people’s minds.

The global research antibodies market is predicted to be a progressive one over the forecast period. The exceptional physiological properties of antibodies make them sought-after for cell research.

According to Transparency Market Research’s latest report on the global antithrombin treatment market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of hereditary antithrombin deficiency to escalate the growth of global antithrombin treatment market.

Beactica Therapeutics AB, the Swedish drug discovery company, and University of Dundee, a top-ranked university in the UK for biological sciences, announced a new research collaboration agreement.

Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim’s position in the cancer vaccine and T-cell engager spaces

Paper published in Journal of Biological Chemistry demonstrates compatibility with downstream manufacturing technologies to help accelerate CAR-T or antibody therapeutics development